Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2026-05-19 @ 9:11 AM
Study NCT ID:
NCT04868604
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2021-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Sponsor:
Clarity Pharmaceuticals Ltd
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CLP05
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None